Navigation Links
Mayo Clinic researchers discover cancer cells may move via wave stimulation

Mayo Clinic researchers have uncovered a new cellular secret that may explain how certain cancers move and spread -- a feature of cancers that makes treatment especially difficult. If the mechanism that drives cancer movement -- also called metastasis -- can be understood well enough to manipulate it, new and better treatments can be developed for patients with metastatic cancers.

Significance of the Mayo Clinic Research

The Mayo researchers focused on odd protrusions observable by microscope on the surface of certain cancer cells: circular waves. Until now, no one has fully understood the function of these waves. The Mayo findings in the current edition of Cancer Research http://cancerres.aacrjournals.org/current.shtml are the first to show one role the waves play. They selectively round up activated growth-promoting proteins from the cell surface and take them to the interior of the cell. Under normal conditions, this process would help terminate signals from these growth-promoting proteins. However, in cancer cells it appears that either these waves may not function properly, or that the internalized proteins may remain active longer, which allows them to "instruct" a cell to acquire cancerous traits such as excessive growth and invasive movement that constitute metastasis. These waves are important for helping to keep these cancer-growth commands at bay.

Studying human pancreatic tumor cells, the Mayo researchers found that the waves store up to half the activated Epidermal Growth Factor Receptors (EGFR) from the surface of the cell and take this cache to the interior of the cells. This is important for understanding cancer because aberrant activation of EGFR can promote the excessive growth typical of cancers.

"These findings have broad implications toward the general understanding of how specific processes in the wave may affect such things as cell growth, cell
'"/>

Source:Mayo Clinic


Page: 1 2 3

Related biology news :

1. Mayo Clinic Researchers Create Obedient Virus; First Step To Use Measles Virus Against Cancer
2. Chronic Sinus Infection Thought To Be Tissue Issue, Mayo Clinic Scientists Show Its Snot
3. Clinical trial to test stem cell approach for children with brain injury
4. Mayo Clinic collaboration discovers protein amplifies DNA injury signals
5. Mayo Clinic researchers challenge sepsis theory
6. Mayo Clinic study finds two genes predict outcome for breast cancer patients
7. Mayo Clinic Cancer Center: Harnessing the measles virus to attack cancer
8. Mayo Clinic collaboration mining of ancient herbal text leads to potential new anti-bacterial drug
9. Mayo Clinic study suggests that a central nervous system viral infection can lead to memory deficits
10. Mayo Clinic: Gene expression profiling not quite perfected in predicting lung cancer prognosis
11. NYU researchers simulate molecular biological clock
Post Your Comments:
(Date:8/20/2008)...nta, Ga. August 20, 2008) Today, the U.S. Environ... of a $2 million grant to the University of Kentuc... nanoparticles affect their ability to enter the b...Results (STAR) grant ever awarded to the Universit...ever awarded by EPA STAR for nanotechnology resear...
(Date:8/20/2008)...AKERS are supposed to protect people from heart at... as well as biological security. , Earlier this y...al School demonstrated how a commercial radio tran...tions from a pacemaker ( New Scientist, 22 March,...tor and adjust the implanted device, but a malicio...
(Date:8/20/2008)...entre for Addiction and Mental Health (CAMH) is pr...on by the Canada Foundation for Innovation (CFI) i...ntervention, treatment and prevention of mental il...e. , This funding from the Large-Scale Institut...tal Fund will allow CAMH to leverage our scientifi...
(Date:8/20/2008)...COLUMBUS, Ohio -- Researchers here have found a wa...gen very efficiently. , A new catalyst makes hyd...kable temperature, and using inexpensive ingredien...olecular engineering at Ohio State University, sai...n others being developed around the world, because...
Breaking Biology News(10 mins):$2M grant awarded to University of Kentucky for research on nanoparticles and human health 2How to stop a new type of heart attack 2Large-scale investment catapults CAMH's mental illness and addiction research forward 2A better way to make hydrogen from biofuels 2A better way to make hydrogen from biofuels 3Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 1Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 2Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 3Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 4Oncolytics Biotech Inc Announces Approval for U K Clinical Trial Investigating REOLYSIN 28R 29 in Combination with Cyclophosphamide 1450 1Oncolytics Biotech Inc Announces Approval for U K Clinical Trial Investigating REOLYSIN 28R 29 in Combination with Cyclophosphamide 1450 2Oncolytics Biotech Inc Announces Approval for U K Clinical Trial Investigating REOLYSIN 28R 29 in Combination with Cyclophosphamide 1450 3Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non Hodgkins Lymphoma 621 1Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non Hodgkins Lymphoma 621 2Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non Hodgkins Lymphoma 621 3Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non Hodgkins Lymphoma 621 4Tracleer 28R 29 Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 619 1Tracleer 28R 29 Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 619 2Tracleer 28R 29 Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 619 3
...stration (FDA) today announced a series of importa...steroidal anti-inflammatory class of drugs, includ...ription (over-the-counter (OTC)) non-selective NSA...ble on the Internet at http://www.fda.gov/cder/dru...otect and advance the health of the millions of Am...
...Polytechnique Fédérale de Lausanne (EPFL) in Switz...ce to silence a mutated gene that causes inherited...tantially delaying both the onset and the progress...results will be published in the April issue of Na...e publication March 13. , In addition to silencing...
...stitute researchers chiseling away at the problem ...nation of how the drugs, main cellular target in b...se medications. The findings are already leading t...neered to circumvent resistance, which is a major ...z, a Howard Hughes Medical Institute investigator ...
...first time mapped multiple complex biological inte...m, enhancing our understanding of how the networks...uence one another. New research published in the O...uch maps can also reveal cryptic interactions and ...t haven,t been observed experimentally. , A living...
Other Biology News:FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 2Silence the gene, save the cell: RNA interference as promising therapy for ALS 2Silence the gene, save the cell: RNA interference as promising therapy for ALS 3Researchers make gains in understanding antibiotic resistance 2Researchers make gains in understanding antibiotic resistance 3Navigating an integrated yeast network 2
(Date:8/21/2008)... NEW YORK, MUNICH, Germany and AMSTERDAM, Neth...thcare and SpePharm Holding, B.V., the,pan-Europea...d that they,have entered into a euro 10 million re...fund SpePharm,s acquisition of Dantrium(R) for Eur...le Pharmaceuticals. At the same,time, TVM Capital,...
(Date:8/20/2008)... VIENNA, Va., Aug. 20 /PRNewswire-USNewswire/ ...0 ranking of the fastest-growing private companies...T) services provider,MicroTech, ranks No. 285 on ... 2008 Inc. 500 list measures revenue growth from 2...U.S.-based, privately held, independent -,no subsi...
(Date:8/20/2008)... INDIANAPOLIS, Ind., Aug. 20 /PRNewswire-First... announced that it has completed the acquisition,o...n Diego-based,biotechnology company focused on dru...y. The completion of the deal followed today,s Spe...SGX stockholders voted in,favor of the merger agre...
(Date:8/20/2008)... Growth Fueled by Popularity with Seniors and ... Marketing, CAMBRIDGE, Mass., Aug. 20 /PRNewswi...hole Health (SWH), a voluntary health care plan fo...ng private company in the,United States., Part of...rowing,companies, SWH had revenue growth of 31,000...
Breaking Biology Technology:TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 2TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 3TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 4TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 5MicroTech Ranks No. 285 on Inc. Magazine's 2008 List of the 500 Fastest Growing Private Companies in America 2Lilly Announces Completion of SGX Acquisition 2Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US 2Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US 3
...d by the Circuit Court of Wisconsin in Milwaukee ...d businesses that acquired Microsoft software ov...ibute nearly $224 million back to them as part of ...against the software giant. , ,The notices are the...awsuits about whether Microsoft violated Wisconsin...
...rs is Japan. In this column, I have covered differ...y and biotech markets (3/10/03, 8/18/03, 3/28/05).... Bio-Jan 2006 Conference in September after a th...rticipate in the 30th anniversary celebration of t...ad started in Chicago and culminated in a series o...
...n will decide whether to change the current long-s... be patentable, an invention must not be "obvious"... it was created by the inventor, and any change in...mpact the ability to procure and enforce patents. ...riefs to appreciate the importance of this case: ...
...ate that the Greater Madison area, while a key U.S...ched the "critical mass" of talent, innovation, an...nts and achieve a state of sustained growth. , ,Bu...convened Tuesday to welcome an emerging drug disco...hern suburb of Madison, a different message emerge...
Other Biology Technology:Microsoft to distribute $224M as part of settlement 2Japan on the rebound: Implications for Midwest 2Japan on the rebound: Implications for Midwest 3Japan on the rebound: Implications for Midwest 4Japan on the rebound: Implications for Midwest 5Japan on the rebound: Implications for Midwest 6Japan on the rebound: Implications for Midwest 7Japan on the rebound: Implications for Midwest 8Japan on the rebound: Implications for Midwest 9Inventions could fall prey to Monday morning quarterbacking 2Inventions could fall prey to Monday morning quarterbacking 3Inventions could fall prey to Monday morning quarterbacking 4Caden Biosciences may signal critical mass 2
Mouse monoclonal antibody raised against a full length recombinant SLC25A11. NCBI Entrez Gene ID = SLC25A11
Mouse monoclonal antibody raised against a partial recombinant TOPORS. Immunogen: TOPORS (NP_005793, 98 a.a. ~ 206 a.a) partial recombinant protein with GST tag. Accession Number: NM_005802
Mouse monoclonal antibody raised against a full length recombinant SNAPC5. NCBI Entrez Gene ID = SNAPC5
...al recombinant NFKBIB. Immunogen: NFKBIB (AAH1...in with GST tag. Protein Sequence: EDGDTALHLAV...GAGLCVAERRGHTALHLACRVGAHACARA Accession: BC015...: 604495, GeneID: 4793 Lot Number: MM9511...
Biology Products: